Allison Kelley
Nurse Practitioner · Athens, GANPI 1952800583
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (58.3%), consulting fees and education — rather than concentrated in one kind of arrangement. 29 manufacturers reported payments, led by Daiichi Sankyo Inc. at 38.3% of the total. Reporting peaked in 2024 at $1,798 and has fallen 88.9% since, to $199 in 2025. Among nurse practitioner clinicians in GA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 107 payments — averaging $30.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Daiichi Sankyo Inc.$1K
- AbbVie$508
- GSK$171
- Lilly USA, LLC$167
- AstraZeneca$105
- Incyte Corporation$100
- plus $961 from 23 others
What the payments were for
- Consulting fees$1,25038%
- Food & beverage$1,90058%
- Education$1123%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Daiichi Sankyo Inc. | 1 | $1,250 |
| AbbVie | 32 | $508 |
| GSK | 11 | $171 |
| Lilly USA, LLC | 11 | $167 |
| AstraZeneca | 7 | $105 |
| Incyte Corporation | 1 | $100 |
| Exact Sciences | 4 | $92 |
| Merck | 3 | $90 |
| Sanofi-aventis U.S. LLC | 5 | $85 |
| Tempus AI, Inc | 1 | $83 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $82 |
| Dexcom, Inc. | 3 | $64 |
| Gilead | 1 | $53 |
| Esperion Therapeutics, Inc. | 3 | $53 |
| Scilex Pharmaceuticals Inc. | 2 | $39 |
| Sanofi | 1 | $36 |
| Amarin Pharma, Inc. | 2 | $36 |
| Amgen | 2 | $35 |
| Pfizer | 2 | $33 |
| Beigene USA, Inc. | 1 | $29 |
| Idorsia Pharmaceuticals US Inc | 2 | $26 |
| Astellas Pharma US Inc | 1 | $19 |
| Array Biopharma Inc | 1 | $18 |
| Sanofi Pasteur Inc. | 1 | $17 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $16 |
| Linus Health, Inc. | 1 | $15 |
| Novo Nordisk | 1 | $14 |
| Genentech USA, Inc. | 1 | $14 |
| Boehringer Ingelheim | 1 | $13 |
How this compares
$3,262 in reported general payments places this provider in the 90th percentile of 3,328 nurse practitioner providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine | 21 | $313 |
Paid to pharmacies, not to this prescriber.
Other nurse practitioner in Athens
- Sue PhelpsAthens$14K
- Andrea MealorAthens$10K
- Victor CzerkasijDalton$505K
- Kennon Mc CollumStockbridge$364K
- Tajuana BradleyJohns Creek$256K
- Jessica AdkinsSavannah$226K
- Janice McAlisterAtlanta$221K
- Laura ElledgeAtlanta$177K
- Afsha HussainiKennesaw$122K
- Elizabeth TyeAlbany$78K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.